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Abstract: We sought to identify the characteristics of men who have sex with men (MSM) who
are opinion leaders on immunization issues and to identify potential opportunities to leverage
their influence for vaccine promotion within MSM communities. Using venue-based sampling,
we recruited and enrolled MSM living in Los Angeles (N = 520) from December 2016 to February
2017 and evaluated characteristic differences in sociodemographic characteristics, health behaviors,
and technology use among those classified as opinion leaders versus those who were not. We also
asked respondents about their past receipt of meningococcal serogroups A, C, W, and Y (MenACWY)
and meningococcal B (MenB) vaccines, as well as their opinions on the importance of 13 additional
vaccines. Multivariable results revealed that non-Hispanic black (aOR = 2.64; 95% CI: 1.17–5.95) and
other race/ethnicity (aOR = 2.98; 95% CI: 1.41–6.29) respondents, as well as those with a history
of an STI other than HIV (aOR = 1.95; 95% CI: 1.10–3.48), were more likely to be opinion leaders.
MenACWY (aOR = 1.92; 95% CI: 1.13–3.25) and MenB (aOR = 3.09; 95% CI: 1.77–5.41) vaccine uptake,
and perceived importance for these and seven additional vaccines, were also associated with being an
opinion leader. The results suggest that the co-promotion of vaccination and other health promotion
initiatives via opinion leaders could be a useful strategy for increasing vaccination among MSM.
Keywords: opinion leadership; MSM; peer health navigation; vaccine measurement; immunization
acceptance; immunization assessment; vaccine promotion
1. Introduction
Although many studies have examined factors associated with immunization hesitancy, refusal,
and acceptance decision-making, as well as immunization coverage that may cluster within networks,
the factors associated with opinion leadership that drive vaccine attitudes and vaccine choices is an
Int. J. Environ. Res. Public Health 2018, 15, 939; doi:10.3390/ijerph15050939 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2018, 15, 939 2 of 12
understudied phenomenon [1–3]. Opinion leadership is characterized as holding considerable social
influence within a network or community, resulting in diffusion of thought, persuasion, and behavior
of others [4,5]. In communities of men who have sex with men (MSM), there have been recent vaccine
preventable disease (VPDs) outbreaks (i.e., meningitis) that have resulted in federal, state, and local
health department immunization recommendations; however, immunization uptake observed among
those surveyed is persistently low [6–8].
MSM communities are characterized by strong, dense social networks, often formed and
maintained through technology [9], which can be valuable targets for immunization interventions [10].
A previous study assessed the five clusters of parental vaccine opinions identified by Gust and
colleagues (2005) and suggested more comprehensive research to assess additional factors associated
with the formation of positive opinion leadership was needed [11]. Thus, improving vaccine uptake
through peer health influencers is an underutilized public health strategy that may offset many health
and social threats including life-years lost, hospitalized days, outpatient visits, loss of productivity,
and significant health costs [12–14].
Opinion leadership has—until now—largely been operationalized within the context of marketing
and consumerism, or for specific health interventions such as HIV prevention among MSM.
For example, marketing based on social networks use opinion leaders as diffusers within their networks
to accelerate the uptake of a new service or product [15–17]. Similarly, peer-led interventions have been
found to significantly increase HIV testing [18,19], knowledge seeking [19], and condom use [19–22]
among MSM in high and middle income countries. These interventions have also been moved onto
social media platforms, such as Facebook. For example, in a study by Young and colleagues (2014) MSM
randomly assigned to a peer opinion leadership group on Facebook that focused on HIV prevention
had lower self-reported risk and higher uptake of HIV home testing kits at the conclusion of a 12-week
study [23].
Our project sought to examine the characteristics associated with opinion leadership for MSM
vaccination in the context of an ongoing meningococcal outbreak in Southern California [24].
We assessed specific vaccine importance to understand what vaccines were important to opinion
leaders and what demographic and behavioral characteristics were unique to opinion leaders.
In addition, we analyzed technology and social media use to understand whether these venues
may be appropriate channels for opinion leader immunization interventions. This work may be
particularly useful in developing and prioritizing future vaccine messages that may be rapidly diffused
through MSM communities.
2. Materials and Methods
2.1. Data Collection
Data were collected from November 2016 through February 2017 as part of a larger project
to understand MSM vaccination response in the context of an ongoing meningitis outbreak in
Southern California [8,24]. Using venue-based convenience sampling, we were able to approach
2250 men about potential participation in the study. Recruiters asked a brief series of standardized
questions to those who expressed interest and recorded responses on a tablet computer to assess their
eligibility. Persons were eligible to enroll if they met the following eligibility criteria: (1) were at
least 18 years old; (2) were assigned male sex at birth; (3) identified as male; (4) reported having sex
with men in the past three months; (5) resided in Los Angeles County; (6) spoke English or Spanish;
and (7) were able to provide informed consent. Eligible MSM were invited in person to take the
15–30-min survey (mean = 17.66 min) delivered by trained interviewers on tablet computers in field
settings. All participants received a $50 cash incentive for completing the survey. The North Campus
Institutional Review Board (IRB) at the University of California, Los Angeles reviewed and approved
the study prior to survey implementation (IRB#16-001745); Emory University subsequently reviewed
it as a secondary data analyses project (IRB#96595).
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2.2. Measures
The outcome of interest was opinion leadership, which we defined using five survey items
regarding the influence of one’s opinion on the vaccination of one’s peers. These survey items were:
(1) “My opinion on vaccines does not seem to count when I talk with others”; (2) “I often influence
other’s opinions about vaccines”; (3) “When they choose their vaccines, others do not turn to me for
advice”; (4) “I often persuade others to get vaccinated”; and (5) “Others rarely come to me for advice
about choosing vaccines”. Each item was scored on a five-point Likert scale of 1 to 5, representing
“Strongly Disagree”, “Disagree”, “Neutral”, “Agree”, and “Strongly Agree” respectively. Together
the standardized Cronbach’s alpha score was 0.67, suggesting moderate internal consistency between
the survey items. Items 1, 3, and 5 were worded in the negative so scores were reverse-coded so
that all item responses were in the positive. Opinion leadership was then created first by summing
scores across each of these variables and then dichotomizing the score so that those who scored 20 or
greater were considered to be opinion leaders and those who scored less than 20 were considered to
be non-opinion leaders. This cut-off was chosen because it represented an overall opinion leadership
score in the top quintile of the scale’s range. Additionally, 13.5% (N = 70) of respondents scored above
20 on the scale, which is consistent with literature describing opinion leaders as “innovators” or “early
adopters” in the top 15% of Rogers’ Diffusion of Innovations curve [25].
We were interested in the predictive ability of 15 vaccination uptake and importance variables
on opinion leadership. These variables were two vaccine uptake questions (yes/no/unsure) of
meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal B (MenB), and 13 vaccine
importance questions (yes/no/unsure) regarding MenACWY; MenB; human papillomavirus (HPV);
hepatitis A (HAV); hepatitis B (HBV); influenza (flu); Haemophilus influenzae type b (Hib); measles,
mumps, rubella (MMR); tetanus, diphtheria, pertussis (Td/Tdap); varicella; zoster; 13-valent
pneumococcal conjugate (PCV13); and 23-valent pneumococcal polysaccharide (PPSV23). For the
analysis, “no” and “unsure” were collapsed together.
To evaluate vaccine confidence, we developed a 10-item MSM Vaccine Confidence Index
(MSM VCI) score using items concerning confidence about vaccines and immunization receipt,
following similar methodology used in the development of three parallel indices for parental vaccine
confidence [26]. These survey items were identified from the 30-item vaccine confidence-related
framework developed by the National Vaccine Advisory Committee (NVAC) and were classified
as they corresponded to the trust-related constructs of the “Information Environment”, in their
“Healthcare Provider”, and “Attitudes and Beliefs” [27]. Each item was scored on a five-point Likert
scale from 1 to 5, representing “Strongly Disagree”, “Disagree”, “Neutral”, “Agree”, and “Strongly
Agree”, respectively. The MSM VCI summary score was created by summing scores across each of
these variables, resulting in a potential range of 10 to 50.
Participants were also asked about their age, race/ethnicity, education, income, employment
status, health insurance, residential zip code, substance use, sexual risk behaviors (e.g., condomless
receptive anal sex in the past six months), STI history, health promoting behaviors (e.g., multivitamin
use and PrEP use among those who self-reported being HIV-negative), and HIV status. We used
condomless receptive anal sex, age, and drug use to develop a risk score using previously established
criteria [28].
Finally, we asked participants about their technology use. Three questions assessed frequency of
individuals’ email, phone, and social media use. We also asked participants to specify the types of
social networking websites (e.g., Facebook, Twitter) they had used in the past 30 days. Additionally,
we asked if participants had ever used the internet to find vaccination information (yes/no) or to find
where to get vaccinated (yes/no).
2.3. Statistical Analysis
We evaluated differences in sociodemographic characteristics, health indicators, and technology
use among those classified as opinion leaders versus those who were not using bivariate and
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multivariable analyses. Variables were identified for the multivariable analysis based on significant
bivariate results. To assess the predictive ability of the 15 vaccination uptake/importance items,
we conducted separate logistic regressions to estimate the increase in the odds of opinion leadership
for those who positively (“yes”) responded to the 15 items compared to those who did not (“no” or
“unsure”). All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA) [29],
with significance defined as α = 0.05
3. Results
3.1. Sociodemograghic Characteristics
Of the 2250 men approached during venue-based sampling, 749 were screened, of which 520
provided valid responses, for an overall response rate of 69%. Respondent sociodemographic
characteristics are described in Table 1. Overall, 70 (13%) were classified as opinion leaders. Participants
were young (M = 33.3, SD = 10.1) and racially/ethnically diverse: White (35.4%), Black/African
American (15.1%), Hispanic (32.5%), and other race/ethnicity (17.0%). Half (51.3%) were college
educated. One-fifth (21.1%) made less than $20,000 per year; the majority (88.3%) had some form
of health insurance. Approximately one-third (34.0%) resided in West Hollywood, a gay enclave in
Los Angeles. Most (89.9%) reported sex with men only, with over a quarter (27.8%) reporting six or
more sexual partners in the past six months. Half (51.9%) reported condomless anal sex (CAS) within
the same time frame. Nearly 12% (11.9%) were HIV-positive.
3.2. Bivariate and Multivariable Results
Opinion leaders and non-opinion leaders had similar sociodemographic characteristics, except
for race/ethnicity. There were more Black/African American (21.7%) or other race/ethnicity (26.1%)
opinion leaders compared to non-opinion leaders (14.1% and 15.4%) respectively (Table 1). There
were greater percentages of participants living with HIV among opinion leaders (20.3%) compared to
non-opinion leaders (10.6%). History of a sexually transmitted infection (STI) other than HIV was also
associated with opinion leadership with 64.3% of opinion leaders having ever been diagnosed with an
STI compared to 45.2% of non-opinion leaders. Additionally, among those who were HIV-negative,
there was also twice as much reported PrEP use for opinion leaders (29.1%) compared to non-opinion
leaders (15.9%). However, these characteristics did not significantly affect those classified as “high risk”;
71.2% of opinion leaders and 65.2% of non-opinion leaders were classified as “high risk”, though this
difference was not significant (p = 0.34).
Technology use among sample participants was high and there were no significant differences
in technology use between the two groups (Table 1). Both opinion leaders and non-opinion leaders,
respectively, had high proportions of Facebook use (85.7% and 86.6%), daily email use (92.8% and
90.9%), daily phone use (98.6% and 98.9%), and daily social media use (95.3% and 89.4%). Additionally,
the majority of opinion leaders and of non-opinion leaders reported using the internet to access
information about vaccinations (64.3% and 57.6%); 51.4% of opinion leaders and 46.2% of non-opinion
leaders reported using the internet to find the locations of vaccination-providers.
We noted statistically significant differences in vaccination uptake, confidence, and importance.
Vaccination uptake and importance tended to be higher for opinion leaders. Higher rates of uptake
for both meningococcal vaccines were seen in this group: approximately 14% higher for MenACWY
and 20% higher for MenB vaccines. The average VCI score for opinion leaders was 43.0 and the
average VCI score for non-opinion leaders was 38.4 (Table 2). We also note greater perceptions of
vaccine importance among opinion leaders for MenACWY, MenB, HPV, HBV, Hib, PCV13, and PPSV23.
Varicella vaccine was received by approximately 5% fewer opinion leaders compared to non-opinion
leaders, however this difference was not statistically significant.
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Table 1. Percentages of opinion leadership (yes/no) by sociodemographic, health, and technology use
covariates using chi-square significance tests.
Variable Non-Opinion Leader(N = 450)
Opinion Leader
(N = 70)
Total
(N = 520) p-Value
Sociodemographics
Age (in Years) 33.1 (32.2, 34.1) 34.4 (32.3, 36.6) 33.3 (32.4, 34.1) 0.33
18–24 21.6 11.4 20.4 0.22
25–44 63.0 72.9 64.2
45–64 14.7 14.3 14.6
65+ 0.7 1.4 0.8
Race/Ethnicity
White 36.9 26.1 35.4 0.03 *
Black 14.1 21.7 15.1
Hispanic 33.6 26.1 32.5
Other 15.4 26.1 17.0
Education (BA or more) 50.6 (45.9, 55.2) 57.1 (45.3, 69.0) 51.3 (47.0, 55.7) 0.31
Employed Full-time 61.7 (57.2, 66.3) 67.1 (55.9, 78.4) 62.4 (58.2, 66.5) 0.39
Income (≥$20,000) 77.8 (73.9, 81.7) 87.1 (79.1, 95.2) 78.9 (75.4, 82.5) 0.07
Insured 88.3 (85.3, 91.3) 88.2 (80.4, 96.1) 88.3 (85.5, 91.1) 0.99
Type of Insurance
Private 57.0 66.7 58.3 0.62
Medicaid/Medicare 25.7 15.3 24.3
Other 5.7 6.1 5.7
Resides in West Hollywood 33.2 (28.8, 37.6) 40.0 (28.2, 51.8) 34.0 (30.0, 38.1) 0.26
Health
HIV-positive serostatus 10.6 (7.7, 13.5) 20.3 (10.6, 30.0) 11.9 (9.1, 14.7) 0.02 *
Uses Alcohol 86.9 (83.7, 90.0) 85.7 (77.3, 94.1) 86.7 (83.8, 89.7) 0.79
Uses Marijuana 50.8 (46.1, 55.4) 55.7 (43.8, 67.6) 51.5 (47.2, 55.9) 0.44
Other Drugs 47.9 (43.3, 52.5) 58.6 (46.7, 70.4) 49.2 (44.9, 53.4) 0.10
History of STI other than HIV 45.2 (40.6, 49.8) 64.3 (52.8, 75.8) 47.7 (43.4, 52.0) <0.01 *
Sexual Partner
Men Only 90.0 88.6 89.9 0.72
Men and Women 10.0 11.4 10.2
No. Sexual Partners (6 months)
0–5 72.7 68.6 72.2 0.77
6–10 13.2 15.7 13.5
11+ 14.1 15.7 14.3
Receptive Condomless Anal Sex 51.2 (46.6, 55.8) 57.1 (45.3, 69.0) 51.9 (47.6, 56.3) 0.36
High Risk 65.2 (60.7, 69.8) 71.2 (60, 82.4) 65.9 (61.7, 70.1) 0.34
PrEP Use † 15.9 (12.2, 19.5) 29.1 (16.7, 41.5) 16.0 (12.9, 19.2) 0.02 *
Multi Vitamin 49.8 (45.1, 54.4) 61.4 (49.7, 73.1) 51.3 (46.9, 55.6) 0.07
Technology
Facebook Usage 86.6 (83.4, 89.8) 85.7(77.3, 94.1) 86.5 (83.5, 89.4) 0.83
Twitter Usage 39.9 (35.3, 44.4) 35.7 (24.2, 47.2) 39.3 (35.1, 43.5) 0.51
Daily Email Users 90.9 (88.2, 93.6) 92.8 (86.5, 99.0) 91.2 (88.7, 93.6) 0.62
Daily Phone Users 98.9 (97.9, 99.9) 98.6 (95.7, 100) 98.9 (97.9, 99.8) 0.82
Daily Social Media Users 89.4 (86.4, 92.3) 95.3 (90, 101) 90.2 (87.6, 92.8) 0.14
Used Internet for Vac. Info 57.6 (53.0, 62.1) 64.3 (52.8, 75.8) 58.5 (54.3, 62.7) 0.29
Used Internet for Vac. Location 46.2 (41.6, 50.8) 51.4 (39.4, 63.4) 46.9 (42.6, 51.2) 0.42
* Indicates significant difference at α = 0.05 level; † Calculated only for those who are HIV negative, N = 396 and 55;
Note: Some percentages may not add to 100.0 due to rounding.
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Table 2. Percentages of opinion leadership (yes vs. no) by vaccine uptake and importance.
Outcome Non-Opinion Leader(N = 450)
Opinion Leader
(N = 70) p-Value
Vaccination Uptake
MenACWY 24.7% (111) 38.6% (27) 0.01 *
MenB 14.4% (65) 34.3% (24) < 0.01 *
Vaccination Importance
HPV 64.4% (290) 77.1% (54) 0.04 *
MenACWY 54.9% (247) 75.7% (53) < 0.01 *
MenB 54.9% (247) 71.4% (50) <0.01 *
HAV 83.8% (377) 87.1% (61) 0.47
HBV 86.7% (390) 95.7% (67) 0.03 *
Flu 63.6% (286) 64.3% (45) 0.91
Hib 42.0% (189) 54.3% (38) 0.05 *
MMR 74.4% (335) 82.9% (58) 0.13
Td/Tdap 80.4% (362) 87.1% (61) 0.18
Varicella 70.7% (318) 65.7% (46) 0.40
Zoster 67.1% (302) 74.3% (52) 0.23
PCV13 41.1% (185) 58.6% (41) < 0.01 *
PPSV23 38.7% (174) 58.6% (41) < 0.01 *0.0
Average VCI a 38.4 43.0 <0.01 *
* Value significant at α = 0.05 level; a 2 sample t-test was performed.
Using a cut threshold of α = 0.10, statistically significant sociodemographic and health correlates
of opinion leadership at the bivariate level were entered into a multivariate model predicting opinion
leadership (Table 3). PrEP use and positive HIV status have a mutually exclusive relationship, meaning
they could not be incorporated in the same regression model. A model with the statistically significant
covariates was run on only HIV positive participants and PrEP was not found to be a predictor for
opinion leadership membership, controlling for the other variables. We therefore excluded PrEP
in following analyses in order to utilize the whole population, HIV positive, and HIV negative
participants. Respondents who reported previously having an STI had greater odds of being an
opinion leader compared to those without history of an STI (aOR = 2.02; 95% CI: 1.39–6.13). Those
who identified as a race/ethnicity other than White, Black, or Hispanic (aOR = 2.91; 95% CI: 1.41–6.29),
and Black/African Americans (aOR = 2.59; 95% CI: 1.15–5.80) had greater odds of being an opinion
leader compared to White respondents. High income participants were more likely to be classified as
an opinion leader compared to those with lower incomes (aOR = 2.36; 95% CI: 1.06–5.28).
Table 3. Multivariable logistic regression for opinion leadership membership.
Outcome aOR 95% CI p-Value
HIV status (ref = negative) 1.69 (0.82, 3.58) 0.16
Race (ref = White)
Black 2.59 (1.15, 5.80) 0.02 *
Hispanic 1.22 (0.59, 2.50) 0.59
Other 2.91 (1.39, 6.13) <0.01 *
Any STI (ref = No) 2.02 (1.14, 3.58) 0.02 *
Other Drug Use (ref = No) 1.35 (0.78, 2.33) 0.28
Multivitamin Use (ref = No) 1.54 (0.89, 2.67) 0.13
High Income (ref = ≤$20,000/year) 2.36 (1.06, 5.28) 0.04 *
* Value significant at α = 0.05 level; Ref = reference group.
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3.3. Logistic Regression Results
We ran 15 additional logistic regression models to test whether vaccination uptake and importance
survey items predicted opinion leadership (Table 4). Two models were run, one with only the vaccine
uptake or importance item and one controlled for variables that were statistically significant in the
opinion leadership membership multivariable model (Table 3). For the unadjusted models, uptake of
MenACWY (OR = 1.92; 95% CI: 1.13–3.25) and MenB (OR = 3.09; 95% CI: 1.77–5.41) were associated
with opinion leadership. Perceiving HPV (OR = 1.86; 95% CI: 1.03–3.36), MenACWY (OR = 2.56;
95% CI: 1.44–4.56), Men B (OR = 2.06; 95% CI: 1.18–3.56), HBV (OR = 3.44; 95% CI: 1.05–11.3), Hib
(OR = 1.64; 95% CI: 0.99–2.72), PCV13 (OR = 2.03; 95% CI: 1.22–3.38), and PPSV23 (OR = 2.24; 95%
CI: 1.34–3.74) vaccines as important were also predictive of opinion leadership. We found relative
consistency between the two sets of models in regard to significant predictors with slight differences in
the degree of prediction with most adjusted odds ratios being slightly lower than their unadjusted
counterparts due to the variations explained by the other included covariates.
Table 4. Multivariable logistic regression models for opinion leadership membership by vaccine outcome.
Outcome OR 95% CI p-Value aOR a 95% CI p-Value
Vaccination Uptake
MenACWY 1.92 (1.13, 3.25) 0.01 * 1.94 (1.11, 3.40) 0.02 *
MenB 3.09 (1.77, 5.41) <0.01 * 2.97 (1.653, 5.34) <0.01 *
Vaccination Importance
HPV 1.86 (1.03, 3.36) 0.04 * 1.88 (1.02, 3.45) 0.04 *
MenACWY 2.56 (1.44, 4.56) < 0.01 * 2.33 (1.28, 4.23) <0.01 *
MenB 2.06 (1.18, 3.56) <0.01 * 1.84 (1.03, 3.27) 0.04 *
HAV 1.31 (0.62, 2.76) 0.47 1.18 (0.55, 2.57) 0.67
HBV 3.44 (1.05, 11.3) 0.03 * 3.32 (0.99, 11.12) 0.05 *
Flu 1.03 (0.61, 1.75) 0.91 0.95 (0.55, 1.6) 0.86
Hib 1.64 (0.99, 2.72) 0.05 * 1.73 (1.01, 2.95) 0.05 *
MMR 1.66 (0.86, 3.20) 0.13 1.58 (0.81, 3.09) 0.18
Td/Tdap 1.65 (0.79, 3.45) 0.18 1.51 (0.71, 3.21) 0.29
Varicella 0.80 (0.47, 1.36) 0.40 0.76 (0.44, 1.34) 0.35
Zoster 1.42 (0.80, 2.51) 0.23 1.41 (0.78, 2.57) 0.26
PCV13 2.03 (1.22, 3.38) < 0.01 * 1.80 (1.06, 3.05) 0.03 *
PPSV23 2.24 (1.34, 3.74) < 0.01 * 1.96 (1.16, 3.34) <0.01 *
* Value significant at α = 0.05 level; a Controlling for covariates significant at α = 0.05 at bivariate level: race/ethnicity,
STI history, income.
We conducted a sensitivity analysis considering “unsure” responses as missing instead of “no”,
which resulted in one notable changes to the results. The new value for Hib vaccine importance
decreased to OR: 1.11 (95% CI: 0.58, 2.13) and was no longer statistically significant (p-value = 0.75);
although we note that the p-value of 0.05 in the original model only just met the threshold for
significance. All other uptake and importance predictors with significant p-values in the original
models resulted in increased ORs and consistent significant p-values during sensitivity testing.
4. Discussion
This study is among the first to examine vaccine opinion leadership among MSM, a group
disproportionately impacted by vaccine preventable illness, including meningitis, HAV, HBV,
and HPV [30–32]. Opinion leaders have an important role to play in the diffusion of innovations in
health, including vaccination messaging. Our results demonstrate that approximately 13.5% of MSM
met criteria for opinion leadership.
Black/African American MSM were more likely to be classified as opinion leaders compared
to their White counterparts. This is notable given the historical disparities in vaccination coverage
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among racial/ethnic minority groups compared to Whites [33–37]. These results are also somewhat
counterintuitive given the documented skepticism regarding biomedical health interventions among
Black/African American MSM [38–41]. One possible explanation for the favorable attitudes
toward vaccination among Black MSM in this context is the intense outreach and engagement
targeted to communities of color during the ongoing meningococcal outbreak in Southern California.
Capitalizing on this association and establishing partnerships with minority community leaders may
be especially important considering vaccination coverage disparities between racial/ethnic minority
and white adults.
The majority of participants in our sample were classified as ‘high risk’ and opinion leaders were
more likely to have been diagnosed with an STI compared to non-opinion leaders. MSM previously
diagnosed with an STI may have more opportunities to interact with healthcare providers and to
engage in conversations explicitly focused on sexual health compared to those who have never been
diagnosed with an STI. Previous research with MSM demonstrates discomfort in discussing sexual
practices with healthcare providers [42,43]. Our findings suggest that key partnerships—such as
the co-location of health promotion activities, STI services, and immunization services—could be
an effective strategy for increasing vaccination and other preventive health interventions among
MSM. A greater percentage of HIV-positive participants were classified as opinion leaders compared
to non-opinion leaders. Although these results were not statistically significant in multivariable
analyses, they suggest the potential utility of engaging HIV-positive MSM in vaccination-related health
promotion. Regular engagement with the healthcare system may enable these men to become aware of
vaccine preventable disease outbreaks more quickly and to disseminate this information to other MSM.
Vaccination recommendations are sometimes different for people living with HIV [44,45] so special
education may be warranted.
Past studies have established the efficacy of social-network level interventions with regard to
HIV prevention [20–22]. Researchers have enlisted and trained opinion leaders to promote HIV
prevention messages during conversation with other MSM, resulting in decreased HIV-risk behaviors
(e.g., CAS) and increased HIV-protective behaviors (e.g., HIV testing, condom use) among their
peers [20–22]. Through dialogue with members of their existing social networks, opinion leaders
can utilize their established personal social influence to cultivate positive attitudes towards, increase
intentions and self-efficacy surrounding, and normalize the discussion of HIV protective behaviors in
their communities [21]. Our data provide needed insight on which factors are associated with opinion
leadership in the context of a meningococcal disease outbreak. Opinion leaders were more likely than
non-opinion leaders to have received MenACWY and MenB vaccination, as well as to consider these
and certain other vaccines as important. These results suggest that MSM who have been vaccinated
may be key partners in influencing others to receive vaccinations during an outbreak.
Given the widespread social media (i.e., Facebook, Twitter, Instagram) and geosocial networking
app (e.g., Hornet, Grindr, Scruff) use by MSM it is important to consider technology-based vaccination
promotion interventions. Opinion leadership interventions have been updated in recent years to
incorporate new technologies. For example, in studies in Los Angeles, Lima, and Taiwan, trained
opinion leaders utilized Facebook to disseminate HIV prevention messages to other internet-using
MSM [19,23,46]. Though results varied by study, participants who received these interventions
were more likely to request HIV testing [23,46], receive HIV tests [19,23,46], and consistently use
condoms during anal sex with sex partners met online [19] compared to control group participants.
In one of these studies, Young and colleagues (2014) found the social media-based opinion leadership
intervention to be feasible and acceptable among the subject pool comprised of primarily Black/African
American and Latino MSM [47]. At least one study that incorporates popular opinion leadership
engagement in online chat rooms for the purpose of HIV prevention is currently under evaluation;
results have not yet been published [48]. The efficacy of social media-based opinion leadership
interventions demonstrated by previous HIV prevention studies, suggests the potential for sending
and receiving health messages via the internet for the purpose of increasing vaccine uptake.
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Our study findings should be interpreted in the context of some limitations. Our data were
cross-sectional, and findings should be interpreted as correlational. Although we used venue-based
sampling, a strategy that would theoretically result in greater generalizability, this sample may not
be representative of all MSM in Los Angeles County. For example, MSM under 18 years of age and
those who did not attend gay-identified venues during the recruitment period were not sampled.
In addition, vaccination outcomes were measured using self-report and therefore may not represent
actual vaccination behavior due to recall, response, and social desirability bias. Because our study was
a rapid response to the unfolding events of the IMD outbreak, we were not able to verify vaccination
status through a third party. Future studies should seek to verify immunization status in collaboration
with health care providers or with data from immunization registries.
5. Conclusions
We examined the characteristics of opinion leaders, including their uptake and attitudes toward
vaccinations, within the context of a meningococcal disease outbreak in Los Angeles, California.
Overall, respondents who identified as Black/African American or as a race/ethnicity other than
White, Black, or Hispanic, and those with a history of an STI (other than HIV) were more likely to be
opinion leaders. In addition, reported receipt of MenACWY and MenB vaccines were associated with
opinion leadership among MSM. Our research builds upon the existing opinion leadership literature
by identifying critical characteristics of opinion leaders in the MSM community. This work may be
particularly useful in developing and prioritizing future vaccine messages that may be rapidly diffused
through MSM communities.
Author Contributions: Ian W. Holloway, Robert Bednarczyk, Vincent L. Fenimore, Elizabeth Wu, Diane Tan, and
Paula M. Frew conceived and designed the experiments; Ian W. Holloway, Robert Bednarczyk, Vincent L. Fenimore,
Elizabeth Wu, Diane Tan, Laura Randall, and Paula M. Frew developed the survey instrument; Ian W. Holloway,
Vincent L. Fenimore, Elizabeth Wu, Diane Tan, and Paula M. Frew collected the data; Ian W. Holloway,
Robert Bednarczyk, Vincent L. Fenimore, Cameron Goldbeck, Elizabeth Wu, Rebecca Himmelstein, Diane Tan,
Chelsea S. Lutz, and Paula M. Frew analyzed the data; Ian W. Holloway, Robert Bednarczyk, Vincent L. Fenimore,
Cameron Goldbeck, Elizabeth Wu, Rebecca Himmelstein, Diane Tan, Laura Randall, Chelsea S. Lutz, and
Paula M. Frew wrote the paper and commented on each stage of the manuscript.
Acknowledgments: The authors wish to thank Patrick Sullivan, Emory University, for his facilitation and support
of this collaboration. This study was supported by a grant from the California HIV/AIDS Research Program
(RP15-LA-007) and a collaborative grant from the Emory University Center for AIDS Research (P30 AI050409).
Robert Bednarczyk is supported by a grant (K01AI106961) from the National Institute for Allergy and Infectious
Diseases, National Institutes of Health.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Atwell, J.E.; Van Otterloo, J.; Zipprich, J.; Winter, K.; Harriman, K.; Salmon, D.A.; Halsey, N.A.; Omer, S.B.
Nonmedical vaccine exemptions and pertussis in California, 2010. Pediatrics 2013, 132, 624–630. [CrossRef]
[PubMed]
2. Omer, S.B.; Enger, K.S.; Moulton, L.H.; Halsey, N.A.; Stokley, S.; Salmon, D.A. Geographic clustering of
nonmedical exemptions to school immunization requirements and associations with geographic clustering
of pertussis. Am. J. Epidemiol. 2008, 168, 1389–1396. [CrossRef] [PubMed]
3. Niyibizi, N.; Schamel, J.; Frew, P.M. Neighborhood influences on seasonal influenza vaccination among older
African Americans in Atlanta, Georgia. J. Immunol. Tech. Infect. Dis. 2016, 5. [CrossRef]
4. Rogers Everett, M. Diffusion of Innovations; The Free Press: New York, NY, USA, 1995.
5. Iyengar, R.; Van den Bulte, C.; Valente, T.W. Opinion leadership and social contagion in new product
diffusion. Mark. Sci. 2011, 30, 195–212. [CrossRef]
6. Los Angeles County Department of Public Health (LAC DPH). Invasive Meningococcal Disease: 2015— Los Angeles
County Epidemiology Report; Los Angeles County Department of Public Health: Los Angeles, CA, USA, 2015.
Int. J. Environ. Res. Public Health 2018, 15, 939 10 of 12
7. NYC Department of Health and Mental Health. Health Department Investigating New Meningitis Cases among
HIV-Positive Men Who Have Sex with Men; Los Angeles County Department of Public Health: Los Angeles,
CA, USA, 2014.
8. Holloway, I.; Wu, E.; Gildner, J.; Fenimore, V.; Frew, P. Vaccination response to an ongoing meningitis
outbreak: Uptake and attitudes among men who have sex with men in Los Angeles, CA. Open Forum
Infect. Dis. 2017, 4 (Suppl. 1), S418. [CrossRef]
9. Grov, C.; Breslow, A.S.; Newcomb, M.E.; Rosenberger, J.G.; Bauermeister, J.A. Gay and bisexual men’s use of
the internet: Research from the 1990s through 2013. J. Sex Res. 2014, 51, 390–409. [CrossRef] [PubMed]
10. Parker, A.M.; Vardavas, R.; Marcum, C.S.; Gidengil, C.A. Conscious consideration of herd immunity in
influenza vaccination decisions. Am. J. Prev. Med. 2013, 45, 118–121. [CrossRef] [PubMed]
11. Oladejo, O.; Allen, K.; Amin, A.; Frew, P.M.; Bednarczyk, R.A.; Omer, S.B. Comparative analysis of the
parent attitudes about childhood vaccines (PACV) short scale and the five categories of vaccine acceptance
identified by gust et al. Vaccine 2016, 34, 4964–4968. [CrossRef] [PubMed]
12. Molinari, N.A.; Ortega-Sanchez, I.R.; Messonnier, M.L.; Thompson, W.W.; Wortley, P.M.; Weintraub, E.;
Bridges, C.B. The annual impact of seasonal influenza in the us: Measuring disease burden and costs. Vaccine
2007, 25, 5086–5096. [CrossRef] [PubMed]
13. Setse, R.W.; Euler, G.L.; Gonzalez-Feliciano, A.G.; Bryan, L.N.; Furlow, C.; Weinbaum, C.M.; Singleton, J.A.
Influenza vaccination coverage—United States, 2000–2010. Morb. Mortal. Wkly. Rep. Surveill. Summ. 2011,
60, 38–41.
14. Kim, J.J. Targeted human papillomavirus vaccination of men who have sex with men in the USA:
A cost-effectiveness modelling analysis. Lancet Infect. Dis. 2010, 10, 845–852. [CrossRef]
15. Jafari Momtaz, N.; Aghaie, A.; Alizadeh, S. Identifying opinion leaders for marketing by analyzing online
social networks. Int. J. Virtual Communities Soc. Netw. 2011, 3, 43–59. [CrossRef]
16. Velente, T.W.; Davis, R.L. Accelerating the diffusion of innovations using opinion leaders. Ann. Am. Acad.
Polit. Soc. Sci. 1999, 566, 55–67. [CrossRef]
17. Katz, E.; Lazarsfeld, P.F. Personal Influence: The Part Played by People in the Flow of Mass Communications;
The Free Press: New York, NY, USA, 1955.
18. Shangani, S.; Escudero, D.; Kirwa, K.; Harrison, A.; Marshall, B.; Operario, D. Effectiveness of peer-led
interventions to increase HIV testing among men who have sex with men: A systematic review and
meta-analysis. AIDS Care 2017, 29, 1003–1013. [CrossRef] [PubMed]
19. Ko, N.Y.; Hsieh, C.H.; Wang, M.C.; Lee, C.; Chen, C.L.; Chung, A.C.; Hsu, S.T. Effects of internet popular
opinion leaders (ipol) among internet-using men who have sex with men. J. Med. Internet Res. 2013, 25, e40.
[CrossRef] [PubMed]
20. Kelly, J.A.; St Lawrence, J.S.; Diaz, Y.E.; Stevenson, L.Y.; Hauth, A.C.; Brasfield, T.L.; Kalichman, S.C.;
Smith, J.E.; Andrew, M.E. HIV risk behavior reduction following intervention with key opinion leaders of
population: An experimental analysis. Am. J. Public Health 1991, 81, 168–171. [CrossRef] [PubMed]
21. Amirkhanian, Y.A.; Kelly, J.A.; Kabakchieva, E.; McAuliffe, T.L.; Vassileva, S. Evaluation of a social network
HIV prevention intervention program for young men who have sex with men in Russia and Bulgaria.
AIDS Educ. Prev. 2003, 15, 205–220. [CrossRef] [PubMed]
22. Amirkhanian, Y.A.; Kelly, J.A.; Kabakchieva, E.; Kirsanova, A.V.; Vassileva, S.; Takacs, J.; DiFranceisco, W.J.;
McAuliffe, T.L.; Khoursine, R.A.; Mocsonaki, L. A randomized social network HIV prevention trial with
young men who have sex with men in Russia and Bulgaria. AIDS 2005, 19, 1897–1905. [CrossRef] [PubMed]
23. Young, S.D.; Holloway, I.; Jaganath, D.; Rice, E.; Westmoreland, D.; Coates, T. Project HOPE: Online social
network changes in an HIV prevention randomized controlled trial for African American and Latino men
who have sex with men. Am. J. Public Health 2014, 104, 1707–1712. [CrossRef] [PubMed]
24. Nanduri, S.; Foo, C.; Ngo, V.; Jarashow, C.; Civen, R.; Schwartz, B.; Holguin, J.; Shearer, E.; Matt Zahn, M.K.H.;
Winter, K.; et al. Outbreak of serogroup c meningococcal disease primarily affecting men who have sex with
men—Southern California, 2016. Morb. Mortal. Wkly. Rep. 2016, 65, 939–940. [CrossRef] [PubMed]
25. Rogers, E.M.; Cartano, D.G. Methods of measuring opinion leadership. Public Opin. Q. 1962, 26, 435–441.
[CrossRef]
26. Frew, P.M.; Chamberlain, A.; Hinman, A.; Nowak, G.; Mendel, J.; Aiken, A.; Randall, L.A.; Hargreaves, A.L.;
Omer, S.B.; Orenstein, W.A.; et al. Development of a Parental Vaccine Confidence Index for Monitoring and
Assessment of Childhood Vaccine Decision-Making; ID Week: San Diego, CA, USA, 2017.
Int. J. Environ. Res. Public Health 2018, 15, 939 11 of 12
27. Orenstein, W.A.; Gellin, B.G.; Beigi, R.H.; Despres, S.; Lynfield, R.; Maldonado, Y.; Mouton, C.; Rawlins, W.;
Rothholz, M.C.; Smith, N.; et al. Assessing the state of vaccine confidence in the United States:
Recommendations from the national vaccine advisory committee. Public Health Rep. 2015, 130, 573–595.
28. Smith, D.K.; Pals, S.L.; Herbst, J.H.; Shinde, S.; Carey, J.W. Development of a clinical screening index
predictive of incident HIV infection among men who have sex with men in the United States. J. Acquir.
Immune Defic. Syndr. 2012, 60, 421–427. [CrossRef] [PubMed]
29. SAS Institute Inc. SAS/STAT Software, Version 9.3; SAS Institute Inc.: Cary, NC, USA, 2011.
30. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases,
13rd ed.; Hamborsky, J., Kroger, A., Wolfe, S., Eds.; Public Health Foundation: Washington, DC, USA, 2015.
31. Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis—United States. 2013.
https://www.cdc.gov/hepatitis/statistics/2013surveillance/pdfs/2013HepSurveillanceRpt.pdf (accessed
on 7 May 2018).
32. Palefsky, J.M.; Rubin, M. The epidemiology of anal human papillomavirus and related neoplasia.
Obstet. Gynecol. Clin. 2009, 36, 187–200. [CrossRef] [PubMed]
33. Gemson, D.H.; Elinson, J.; Messeri, P. Differences in physician prevention practice patterns for white and
minority patients. Community Health 1988, 13, 53–64. [CrossRef]
34. Singleton, J.A.; Santibanez, T.A.; Wortley, P.M. Influenza and pneumococcal vaccination of adults aged ≥65:
Racial/ethnic differences. Am. J. Prev. Med. 2005, 29, 412–420. [CrossRef] [PubMed]
35. Lu, P.J.; Nuorti, J.P. Uptake of pneumococcal polysaccharide vaccination among working-age adults with
underlying medical conditions, United States, 2009. Am. J. Epidemiol. 2012, 175, 827–837. [CrossRef]
[PubMed]
36. Williams, W.W.; Lu, P.-J.; O’Halloran, A.; Bridges, C.B.; Pilishvili, T.; Hales, C.M.; Markowitz, L.E.
Non-influenza vaccination coverage among adults, United States, 2012. Morb. Mortal. Wkly. Rep. 2014,
63, 95–102.
37. Lu, P.J.; O’Halloran, A.; Williams, W.W.; Lindley, M.C.; Farrall, S.; Bridges, C.B. Racial and ethnic disparities
in vaccination coverage among adult populations. Am. J. Prev. Med. 2015, 49, 951–956. [CrossRef] [PubMed]
38. Brandon, D.T.; Isaac, L.A.; LaVeist, T.A. Tuskegee and trust in medical care: Is tuskegee responsible for race
differences in mistrust of medical care? J. Natl. Med. Assoc. 2005, 97, 951–956. [PubMed]
39. Scharff, D.P.; Mathews, K.J.; Jackson, P.; Hoffsuemmer, J.; Martin, E.; Edwards, D. More than tuskegee:
Understanding mistrust about research participation. J. Health Care Poor Underserved 2010, 21, 879–897.
[CrossRef] [PubMed]
40. Bogart, L.M.; Wagner, G.J.; Green, H.D., Jr.; Mutchler, M.G.; Klein, D.J.; McDavitt, B.; Lawrence, S.J.;
Hilliard, C.L. Medical mistrust among social network members may contribute to antiretroviral treatment
nonadherence in african americans living with HIV. Soc. Sci. Med. 2016, 164, 133–140. [CrossRef] [PubMed]
41. Dale, S.K.; Bogart, L.M.; Wagner, G.J.; Galvan, F.H.; Klein, D.J. Medical mistrust is related to lower
longitudinal medication adherence among African-American males with HIV. J. Health Psychol. 2016,
21, 1311–1321. [CrossRef] [PubMed]
42. Wheldon, C.W.; Daley, E.M.; Buhi, E.R.; Baldwin, J.A.; Nyitray, A.G.; Giuliano, A.R. HPV vaccine
decision-making among young men who have sex with men. Health Educ. J. 2017, 76, 52–65. [CrossRef]
43. Oldenburg, C.E.; Perez-Brumer, A.G.; Hatzenbuehler, M.L.; Krakower, D.; Novak, D.S.; Mimiaga, M.J.;
Mayer, K.H. State-level structural sexual stigma and HIV prevention in a national online sample of
HIV-uninfected men who have sex with men in the United States. AIDS 2015, 29, 837–845. [CrossRef]
[PubMed]
44. Schuster, J.E.; Sawyer, M.H.; O’Leary, S.; Kimberlin, D. Update from the advisory committee on immunization
practices. J. Pediatr. Infect. Dis. Soc. 2016, 5, 101–104. [CrossRef] [PubMed]
45. MacNeil, J.R.; Rubin, L.G.; Patton, M.; Ortega-Sanchez, I.R.; Martin, S.W. Recommendations for use of
meningococcal conjugate vaccines in HIV-infected persons—Advisory committee on immunization practices,
2016. Morb. Mortal. Wkly. Rep. 2016, 65, 1189–1194. [CrossRef] [PubMed]
46. Young, S.D.; Cumberland, W.G.; Nianogo, R.; Menacho, L.A.; Galea, J.T.; Coates, T. The HOPE social media
intervention for global HIV prevention: A cluster randomized controlled trial in Peru. Lancet HIV 2014,
2, e27–e32. [CrossRef]
Int. J. Environ. Res. Public Health 2018, 15, 939 12 of 12
47. Young, S.D.; Cumberland, W.G.; Lee, S.-J.; Jaganath, D.; Szekeres, G.; Coates, T. Social networking
technologies as emerging tools for HIV prevention: A cluster randomized trial. Ann. Intern. Med. 2013, 159,
318–324. [CrossRef] [PubMed]
48. Gruskin, E.P.; Hart, S.; Gordon, N.; Ackerson, L. Patterns of cigarette smoking and alcohol use among
lesbians and bisexual women enrolled in a large health maintenance organization. Am. J. Public Health 2001,
91, 976–979. [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
